Critical evaluation of latanoprostene bunod in the treatment of glaucoma

Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F receptor agonist in clinical development for intraocular pressure lowering in open-angle glaucoma and ocular hypertension. Currently in Phase III clinical trials in the USA, European Union, and Japan, LBN has demonstrated pr...

Full description

Saved in:
Bibliographic Details
Published in:Clinical ophthalmology (Auckland, N.Z.) N.Z.), 2016-01, Vol.10, p.2035-2050
Main Authors: Garcia, Giancarlo A, Ngai, Philip, Mosaed, Sameh, Lin, Ken Y
Format: Article
Language:English
Subjects:
Acids
Analysis
clinical trial
Clinical trials
Compliance
Drug dosages
Drug therapy
Extracellular matrix
Glaucoma
glaucoma medical treatment
Hypertension
Kinases
latanoprostene bunod
Nitric oxide
ocular hypertension
Patient compliance
Patients
Permeability
Prostaglandins
Qualitative research
Quality of life
Review
uveoscleral outflow
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F receptor agonist in clinical development for intraocular pressure lowering in open-angle glaucoma and ocular hypertension. Currently in Phase III clinical trials in the USA, European Union, and Japan, LBN has demonstrated promising efficacy while maintaining safety and tolerability. We review preclinical and clinical developmental efforts and evaluate the potential role of LBN monotherapy in the management of open-angle glaucoma and ocular hypertension. The current LBN clinical development program comprises eight trials, four of which have resulted in publication of complete methodology and outcomes. We additionally pool adverse events data to determine incidences across three pivotal studies. Evidence thus far indicates that LBN may be a safe and effective ocular hypotensive agent, although the potential neuroprotective effects and the impact on visual field loss remain to be evaluated.
ISSN:1177-5467
1177-5483
1177-5483
DOI:10.2147/OPTH.S103985